Health and Fitness Health and Fitness
Mon, April 18, 2011
[ Mon, Apr 18th 2011 ] - Market Wire
00 a.m. ET
Sun, April 17, 2011
Fri, April 15, 2011
Thu, April 14, 2011
Wed, April 13, 2011
Tue, April 12, 2011
Mon, April 11, 2011
Sun, April 10, 2011
Sat, April 9, 2011
Fri, April 8, 2011
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ] - Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011
Tue, March 29, 2011
[ Tue, Mar 29th 2011 ] - Market Wire
30pm CDT

RXi Pharmaceuticals to Webcast Presentation at BioCentury Future Leaders in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2011/ .. -leaders-in-the-biotech-industry-conference.html
Published in Health and Fitness on Friday, April 8th 2011 at 4:25 GMT by Market Wire   Print publication without navigation


WORCESTER, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the Companya™s President and Chief Executive Officer, Mark J. Ahn, Ph.D., will present a corporate overview to include the companya™s recent announcement of their intent to acquire Apthera at BioCenturya™s Future Leaders Conference on Friday, April 15, 2011 at 9:00 a.m. ET, at the Millennium Broadway Hotel & Conference Center in New York City.

The acquisition provides RXi with a late stage product candidate, NeuVaxa", a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer, not eligible for Herceptin®, which is expected to enter Phase III clinical trials in the first half of 2012. The Companya™s first RNAi product, RXI-109 which targets CTGF (connective tissue growth factor) for anti-scarring, remains on track for an investigational new drug (IND) application filing this year.

A live webcast of the presentation will be available from the aInvestor Relationsa section of the Company's website, [ www.rxipharma.com ]. A replay of the presentation will be available for 30 days.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies. Based on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXia™s first RNAi product candidate, RXI-109 which targets CTGF (connective tissue growth factor), is scheduled to commence human clinical trials in anti-scarring in early 2012. RXi recently accelerated its product development focus with the acquisition of NeuVaxa" which is slated to commence Phase III clinical trials in low-to-intermediate HER2+ breast cancer patients, not eligible for Herceptin®, in the first half of 2012. For more information please visit us at [ www.rxipharma.com ]


Publication Contributing Sources